Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander Garrelfs, Yaacov Frishberg, Sally Hulton, Michael Koren, William O’riordan, Pierre Cochat, Georges Deschênes, Hadas Shasha-Lavsky, Jeffrey Saland, William Van’t Hoff, Daniel Fuster, Daniella Magen, Shabbir Moochhala, Gesa Schalk, Eva Simkova, Jaap Groothoff, David Sas, Kristin Meliambro, Jiandong Lu, Marianne Sweetser, Pushkal Garg, Akshay Vaishnaw, John Gansner, Tracy Mcgregor, John Lieske

Open source

DOI: 10.1056/nejmoa2021712
Published: 2021-04
Container: New England Journal of Medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2021712,
  title = {Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1},
  author = {Sander Garrelfs and Yaacov Frishberg and Sally Hulton and Michael Koren and William O’riordan and Pierre Cochat and Georges Deschênes and Hadas Shasha-Lavsky and Jeffrey Saland and William Van’t Hoff and Daniel Fuster and Daniella Magen and Shabbir Moochhala and Gesa Schalk and Eva Simkova and Jaap Groothoff and David Sas and Kristin Meliambro and Jiandong Lu and Marianne Sweetser and Pushkal Garg and Akshay Vaishnaw and John Gansner and Tracy Mcgregor and John Lieske},
  year = {2021},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa2021712},
  url = {https://doi.org/10.1056/nejmoa2021712}
}

RIS

TY  - JOUR
TI  - Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
AU  - Sander Garrelfs
AU  - Yaacov Frishberg
AU  - Sally Hulton
AU  - Michael Koren
AU  - William O’riordan
AU  - Pierre Cochat
AU  - Georges Deschênes
AU  - Hadas Shasha-Lavsky
AU  - Jeffrey Saland
AU  - William Van’t Hoff
AU  - Daniel Fuster
AU  - Daniella Magen
AU  - Shabbir Moochhala
AU  - Gesa Schalk
AU  - Eva Simkova
AU  - Jaap Groothoff
AU  - David Sas
AU  - Kristin Meliambro
AU  - Jiandong Lu
AU  - Marianne Sweetser
AU  - Pushkal Garg
AU  - Akshay Vaishnaw
AU  - John Gansner
AU  - Tracy Mcgregor
AU  - John Lieske
PY  - 2021
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2021712
UR  - https://doi.org/10.1056/nejmoa2021712
ER  -

APA

Garrelfs, S., Frishberg, Y., Hulton, S., Koren, M., O’riordan, W., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J., Hoff, W. V., Fuster, D., Magen, D., Moochhala, S., Schalk, G., Simkova, E., Groothoff, J., Sas, D., Meliambro, K., Lu, J., Sweetser, M., Garg, P., Vaishnaw, A., Gansner, J., Mcgregor, T., & Lieske, J. (2021). Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2021712

Source records

hal · retrieved 2026-09-27T03:58:23.371Z